Postoperative pain: late pain (6 weeks postoperatively) VAS 0 to 10 Verbal reporting scale No pain‐mild pain‐moderate pain‐severe pain (converted to numerical scale (0 to 3, 3 to 6, 6 to 10)
1 finding from 1 review
Adverse events (moderate) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (moderate) compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Adverse events (moderate) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (moderate) compared with stereotactic radiosurgery plus WBRT (very low certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA probably leads to lower moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS leads to lower moderate to severe exacerbations: high‐risk population compared with LABA (high certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS probably leads to lower moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA leads to lower moderate to severe exacerbations: high‐risk population compared with LABA (high certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with fibromyalgia
Mirtazapine may leads to higher participant‐reported pain relief of 30% or greater (moderate… compared with placebo (low certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults receiving chemotherapy alone for colorectal cancer
Intestinal trefoil factor (ITF), oral spray led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
2 findings from 1 review
Oral mucositis (moderate to severe) · Adults receiving bone marrow/stem cell transplantation after conditioning therapy for haematological cancers
Erythropoietin mouthwash led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (moderate to severe) compared with placebo (low certainty).
3 findings from 1 review
RR 0.89 [0.80, 0.99]
6 studies · 852 participants
Low
RR 0.91 [0.83, 1.00]
3 studies · 471 participants
Moderate
RR 0.56 [0.45, 0.70]
4 studies · 344 participants
Moderate